Business
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025.
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025.","length":322,"tagName":"p"},{"type":"image","alt":"Sera Prognostics (PRNewsfoto/Sera Prognostics, Inc.)","displaySize":"","headline":null,"caption":"Sera Prognostics (PRNewsfoto/Sera Prognostics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":90,"url":"https://media.zenfs.com/en/prnewswire.com/d1d944ffbad708c79d61709e5cb91780"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g3shuPcAHtDCV.D5czkFkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1d944ffbad708c79d61709e5cb91780","width":400,"height":90}},"href":"https://mma.prnewswire.com/media/1670603/Sera_Prognostics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrators.","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"Pursuing Medicaid opportunity, which represents approximately half of the market opportunity for Sera's PreTRM® Test; in discussions with several Medicaid plans across three states for PreTRM test implementation pilots.","length":223,"tagName":"p"}]},{"val":[{"type":"text","content":"Expecting to have strong presence at upcoming American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical & Scientific Meeting May 16-18. Sera plans to meet with attendees to cultivate interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm.","length":313,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed Jeff Elliott to Board of Directors, making talented board deeper with his breadth and depth of expertise in commercially scaling companies in our sector.","length":163,"tagName":"p"}]}],"tagName":"u...